A new oral anticoagulant has recently received regulatory

approval for stroke prevention in patients with atrial fibrillation. Within the

first year of clinical use, clinicians reported that patients with peripheral

arterial disease experienced unexpected improvements in their symptoms while

taking the medication. This effect was not observed during earlier clinical

trials.

What is the most likely reason for this potential new indication

being observed during post-marketing surveillance?